In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
BRITISH JOURNAL OF PHARMACOLOGY(1997)
摘要
1 The present studies were designed to measure the affinity of UP 269-6, a newly developed angiotensin AT(1) receptor antagonist, for vascular AT(1) receptors from normotensive and hypertensive rats and to investigate in vitro, its effects on angiotensin II (AII)-induced hyperplasia and hypertrophy of vascular smooth muscle cells (VSMC). In addition the in vivo effects of UP 269-6 on neointimal proliferation in a carotid artery balloon injury in normotensive rats were also investigated. 2 UP 269-6 selectively inhibited [I-125]-Sar(1)-IIe(8)-AII binding to vascular AT(1) receptors present on VSMC derived from normotensive Wistar rat and from SHR (K-i = 16.6 +/- 3.6 nM and 7.5 +/- 2.0 nM, respectively). In comparison, losartan and its metabolite, EXP 3174, inhibited [I-125]-Sar(1)-Ile(8)-AII binding to vascular AT(1) receptors derived from both cell models with K-i values slightly lower (losartan) and higher (EXP 3174), respectively, than that of UP 269-6. 3 AII (1 mu M) induced a weak and variable hyperplastic response (4 to 32% increase in cell number) in Wistar rat VSMC after 96 h. 4 AII (1 mu M) induced a time-dependent increase in cell number in VSMC from SHR. UP 269-6 inhibited concentration-dependently this effect with an IC50 value of 159 +/- 58 nM. Losartan was clearly less potent and EXP 3174 showed nearly the same inhibitory potency, compared to UP 269-6. UP 269-6 (1 mu M) inhibited nearly completely the action of AII. 5 AII (500 nM) caused maximal stimulation of protein synthesis in Wistar rat VSMC (117+/-36%). UP 269-6, losartan and EXP 3174 totally inhibited this stimulation with IC50 values of 28 +/- 6 nM, 3504 +/- 892 nM and 21 +/- 3 nM, respectively. 6 AII (50 nM) induced maximal stimulation of protein synthesis in SHR VSMC (237 +/- 67%). UP 269-6, losartan and EXP 3174 totally inhibited this stimulation with IC50 values of 16 +/- 3 nM, 282 +/- 122 nM and 3.3 +/- 1.0 nM, respectively. 7 UP 269-6 (75 mg kg(-1) day(-1)) administered orally in the diet for 20 days induced a 38% reduction in neointimal area and a 36% reduction in neointima/media ratio associated with the intimal thickening induced by carotid artery balloon injury. 8 In conclusion, UP 269-6 was shown to be a potent antiproliferative agent both in vitro on AII-induced hyperplasia and hypertrophy of VSMC derived from normotensive and hypertensive rats. and in vitro upon intimal thickening induced by carotid artery balloon injury in the rat.
更多查看译文
关键词
angiotensin II receptor,vascular smooth muscle cells (VSMC),[I-125]-Sar1-Ile8 binding,normotensive rat VSMC model,hypertensive rat VSMC model,hyperplasia,hypertrophy,neointimal proliferation,UP 269-6,losartan,EXP 3174
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要